Health Care [ 7/12 ] | Pharmaceuticals [ 40/74 ]
NASDAQ | Common Stock
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis.
It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.13 Decreased by -62.50% | -0.12 Decreased by -8.33% |
| Aug 8, 24 | -0.12 Decreased by -71.43% | -0.11 Decreased by -9.09% |
| May 7, 24 | -0.11 Decreased by -83.33% | -0.09 Decreased by -22.22% |
| Mar 20, 24 | -0.08 Decreased by -33.33% | -0.09 Increased by +11.11% |
| Nov 9, 23 | -0.08 Increased by +33.33% | -0.09 Increased by +11.11% |
| Aug 10, 23 | -0.07 Increased by +50.00% | -0.08 Increased by +12.50% |
| May 11, 23 | -0.06 Increased by +75.00% | -0.07 Increased by +14.29% |
| Mar 16, 23 | -0.06 Increased by +78.57% | -0.10 Increased by +40.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -13.24 M Decreased by -72.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.35 M Decreased by -72.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.90 M Decreased by -70.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 176.00 K Increased by +N/A% | -7.82 M Decreased by -42.10% | Decreased by -4.44 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.70 M Increased by +6.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.14 M Increased by +11.26% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -6.40 M Increased by +12.66% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -5.50 M Increased by +35.40% | Decreased by N/A% Decreased by N/A% |